Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients

Antiviral Therapy

Volumn 12, Issue 4, 2007, Pages 523-529

  Mira, José A ^a,g   Valera Bestard, Bárbara ^b,g   Arizcorreta Yarza, Ana ^c,g   González Serrano, Mercedes ^d,g   Torre Cisneros, Julián ^e,g   Santos, Ignacio ^f   Vergara, Salvador ^a,g   Gutiérrez Valencia, Alicia ^b,g   Girón González, José A ^c,g   Macías, Juan ^a,g   López Cortés, Luis F ^b,g   Pineda, Juan A ^a,g  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g Grupo para el Estudio de Las Hepat Viricas de la Soc Andaluza de Enfermedades Infecciosas (SAEI)   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON ALFA-2B; MALE; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 34447273835     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Torriani FJ, Rodríguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
2. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. A randomized controlled trial. JAMA 2004; 292:2839-2848.
3. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-459.
4. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18:F27-F36.
5. Mira JA, Torre-Cisneros J, Merino D, et al. Efficacy of pegylated interferon plus ribavirin in HIV/HCV co-infection outside of well-circumscribed clinical trials: the Andalusian multicenter study. 13th Conference on Retroviruses & Opportunistic Infections. Denver, CO, USA, 5-9 February 2006. Abstract 861.
6. Moreno L, Quereda C, Moreno A, et al. Pegylated interferon alfa 2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 2004; 18:67-73.
7. Fried MW, Shiffamn ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
9. Hadziyannis S, Sette H, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140:346-355.
10. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36:S145-S151.
11. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.
12. National Institutes of Health Consensus on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19:1-46.
13. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615-624.
14. Soriano V, Miró JM, García-Samaniego J, et al. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J Viral Hepat 2004; 11:2-17.
15. Soriano V, Núñez M, Camino N, et al. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antivir Ther 2004; 9:505-509.
16. Cargnel A, Angeli E, Mainini A, et al. Open, randomized, multicentre Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir Ther 2005; 10:309-317.
17. Santin M, Shaw E, García MJ, et al. Efficacy and safety of pegylated interferon-α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS Res Hum Retroviruses 2006; 22:315-320.
18. Ballesteros AL, Franco S, Fuster D, et al. Early dynamics on peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. AIDS 2004; 18:59-66.
19. Hopkins S, Lambourne J, Farrell G, et al. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals. HIV Med 2006; 7:248-254.
20. Moreno A, Bárcena R, García-Garzón S, et al. Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus. J Viral Hepat 2006; 13:466-473.
21. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-374.
22. Dieterich D, Duff F, Sulkowski M, et al. Sustained virologic response (SVR) in HIV-HCV-co-infected patients with HCV genotype 1 (G1) infection who have a rapid virological response (RVR) at week 4 of treatment with peginterferon α-2a (40 KD) (PEG-IFNα-2a, PEGASYS®) plus ribavirin (RBV, COPEGUS®): AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT). 13th Conference on Retroviruses & Opportunistic Infections. Denver, CO, USA, 5-9 February 2006. Abstract 856.
23. Sarrazin C, Gartner BC, Sizmann D, et al. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol 2006; 44:729-737.
24. Caliendo AM, Valsamakis A, Zhou Y, et al. Multilaboratory comparison of hepatitis C virus viral load assays. J Clin Microbiol 2006; 44:1726-1732.
25. Lissen E, Clumeck N, Sola R, et al. Histological response to pegIFN[alpha]-2a (40KD) plus ribavirin in HIV-hepatitis C virus coinfection. AIDS 2006; 20:2175-2181.
26. Pérez-Olmeda M, Núñez M, Romero M, et al. Pegylated IFNα2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17:1023-1028.
27. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352:2609-2617.
28. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40 KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-527.
29. Crespo M, Sauleda S, Esteban JI, et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha 2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hep 2007; 14:228-238.